![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Asian Patients With Chronic Genotype 2 HCV Infection Achieve 98% Sustained Virologic Response Following
12-Week Administration of Sofosbuvir in Combination With Ribavirin: Integrated Analysis of Phase 3 Multicenter Studies
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Masao Omata,1 Young-Suk Lim,2 Wan-Long Chuang,3 Jia-Horng Kao,4 Bing Gao,5 Shampa De-Oertel,5 Jenny C. Yang,5 Hongmei Mo,5 Diana Brainard,5 Steven J. Knox,5 John G. McHutchison,5 Masashi Mizokami,6 Kwang-Hyub Han7
1Yamanashi Prefectural Hospital Organization, Yamanashi, Japan; 2Asan Medical Center, University of Ulsan College of Medicine Seoul, South Korea; 3Kaohsiung Medical University, Kaohsiung, Taiwan; 4National Taiwan University College of Medicine, Taipei, Taiwan;
5Gilead Sciences, Inc., Foster City, CA; 6National Center for Global Health and Medicine, Tokyo, Japan; 7Yonsei University College of Medicine, Seoul, South Korea
![AASLD1.gif](../images/121815/121815-4/AASLD1.gif)
![AASLD2.gif](../images/121815/121815-4/AASLD2.gif)
![AASLD3.gif](../images/121815/121815-4/AASLD3.gif)
![AASLD4.gif](../images/121815/121815-4/AASLD4.gif)
![AASLD5.gif](../images/121815/121815-4/AASLD5.gif)
![AASLD6.gif](../images/121815/121815-4/AASLD6.gif)
![AASLD7.gif](../images/121815/121815-4/AASLD7.gif)
![AASLD8.gif](../images/121815/121815-4/AASLD8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|